Torrent Pharmaceuticals has officially released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by independent practicing company secretaries, confirms the company’s full adherence to all applicable statutory and corporate governance standards. This disclosure highlights the company’s commitment to transparency, regulatory compliance, and robust internal policies throughout the previous fiscal year.
Commitment to Corporate Governance
The latest compliance review for the fiscal year ending March 31, 2026, underscores Torrent Pharmaceuticals’ dedication to maintaining high standards of governance. The assessment verified that the company has effectively complied with all statutory requirements, internal policies, and disclosure mandates, ensuring that all corporate activities align with regulatory frameworks.
Key Governance Highlights
The review encompassed a thorough examination of company records, filings, website disclosures, and board processes. Notable findings from the compliance assessment include:
- Strict adherence to secretarial standards and board-approved corporate policies.
- Maintenance of a fully functional and transparent website for stakeholder information.
- Confirmation that all directors remain in good standing, with no disqualifications recorded.
- Proper oversight of material subsidiaries and robust disclosure of all related party transactions.
- Effective performance evaluation processes for the Board, independent directors, and internal committees.
Transparency and Future Outlook
The report confirms that no adverse actions were taken against the company, its promoters, or its directors by market authorities during the review period. By maintaining rigorous control over information flow and ensuring timely submissions, Torrent Pharmaceuticals continues to foster a culture of accountability and shareholder trust, positioning itself for sustained growth and operational stability in the coming fiscal year.
Source: BSE
